FDA approves first oral pill for postpartum depression

The collaboration between Biogen and Sage Therapeutics to develop Zurzuvae has proven successful. The FDA has approved the oral pill specifically for the treatment of postpartum depression (PPD), making it the first of its kind in a class of antidepressants aimed specifically at new mothers. According to CDC research, one in eight women will experience symptoms of postpartum depression. Symptoms of PPD can occur quite intensely after birth and can be dangerous as they can interfere with the new mother's ability to function. The long-awaited approval is due to two randomized double-blind studies that proved the effectiveness of the drug.

A key feature of Zurzuvae is that the drug is supposed to work in just a few days and should be taken for up to two weeks. Prior to this once-daily oral pill, the most common treatment plan for PPD required an IV injection. This meant that administration by a healthcare provider in a hospital or healthcare facility was required. With this approval, Zurzuvae will be able to expand access and reach more women discharged from hospitals.

The catch is that the drug can impact a patient's ability to drive and cause extreme drowsiness. Additionally, the drug's warning label emphasizes that, like most antidepressants, the drug may cause an increased risk of suicidal ideation. To top it off, Zurzuvae can also harm the fetus. Patients taking the drug should use contraception while taking the pill and for one week after taking Zurzuvae.